GLP-1 Boxed Warnings: Which Drugs Have One in 2026?

The short answer

GLP-1 boxed warnings most often cover thyroid C-cell tumors. In this 2026 U.S. label review, most GLP-1 medicines carry one. A warned product is a hard “do not use” if you have a personal or family history of medullary thyroid carcinoma (MTC), or MEN 2. The warning does not prove these drugs cause cancer in people.

What changes that answer: not every GLP-1-containing product has one. Soliqua and Byetta do not. Foundayo does — even though its own rodent cancer studies produced no tumors. That sounds like a mistake. It is not, and once you understand why, the whole warning makes a lot more sense.

Read this page if:

• You opened the label, saw a black border and the word tumors, and your stomach dropped
• Your doctor said “there’s a black box warning” and then moved on
• Somebody in your family had thyroid cancer and you do not know if that counts
• You want to check your exact medicine, not a general answer about “GLP-1s”

This page cannot:

• Diagnose you
• Tell you your personal cancer risk
• Clear you to start, stop, skip, or switch anything
• Replace a conversation with the person who writes your prescription

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

What we actually verified

On August 5, 2026, we opened 13 U.S. brand-name label records on DailyMed and read them ourselves. Those records cover the 14 product and formulation entries in the chart below because one DailyMed record covers both Rybelsus and Ozempic tablets.

For every record, we checked whether a Boxed Warning section is actually there, what Section 4 (Contraindications) says, what the thyroid safety language says, and the current prescribing-information revision marker.

We also opened Section 13.1 of several labels. That is the part almost nobody reads. It is where the actual animal-study results live — the species, the tumor findings, and the exposure multiples. It is the reason this page can tell you things most summaries cannot.

We did not guess a warning from the drug class. That shortcut is exactly how the two current no-box exceptions get missed.

Scope: U.S. brand-name label records. Not every generic, repackaged, discontinued, compounded, or non-U.S. product. DailyMed is a label database, not a live pharmacy-stock feed. Labels change. Ours has a date on it.

Quick answers, before you scroll

GLP-1 boxed warnings by drug: which medicines have one?

Twelve of the 14 product and formulation entries we checked — covering 11 of the 13 DailyMed records — carry a Boxed Warning about thyroid C-cell tumors. Byetta and Soliqua do not. Every entry that has the warning also lists a personal or family history of MTC and MEN 2 as reasons not to use it.

Here is the whole thing in one place.

The 2026 chart

A label record is not the same thing as pharmacy stock. DailyMed lists a marketing end date of October 31, 2025 for Bydureon BCise. The current Byetta record lists NDC marketing end dates of November 30 and December 31, 2026. Those dates tell you what is in the label record; they do not promise that a local pharmacy has stock.

On generics and repackaged products: this ledger tracks the brand-name records above. If you are holding a generic or repackaged product, check the exact label that came with your prescription instead of assuming every NDC is represented here.

The two that do not have one — and what that does not mean

Byetta and Soliqua are the current exceptions in this chart. Before you read anything into that, read this sentence twice:

No Boxed Warning does not mean safer. Both products still carry serious warnings in other parts of their labels. All “no Boxed Warning” means here is that the current label does not put this thyroid C-cell risk inside a Boxed Warning section.

Here is why the split is more complicated than it first looks.

Why the label pattern is not controlled by one dose cutoff

We pulled the actual numbers from Section 13.1 of four labels. The result is not a clean formula. It is proof that you have to read the exact product label.

How to read the exposure numbers: each multiple compares the animal’s drug exposure with the maximum human exposure used in that specific label. A “2×” in one drug label is not the same dose as a “2×” in another.

Read that table again slowly, because it kills the easy story.

Semaglutide and liraglutide labels contain thyroid-tumor findings at clinically relevant exposure levels. Lixisenatide’s tumor findings sit at much higher exposure multiples, yet the current Soliqua label still contains serious warnings outside a box. Foundayo produced no tumors in its rodent cancer studies and still carries the box.

There is no honest one-number rule that lets a reader predict the Boxed Warning. The final label is product-specific. That is why “all GLP-1s have the same warning” and “no box means no risk” are both bad shortcuts.

Foundayo: the strangest boxed warning in the class

Foundayo was approved on April 1, 2026. It is a once-daily GLP-1 receptor agonist tablet, and its Boxed Warning contains a sentence that does not appear in the other labels we checked:

“Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents.” — FOUNDAYO Prescribing Information, Boxed Warning, revised 4/2026

Section 13.1 backs it up. In a two-year rat study at three exposure levels — reaching about 26 times the maximum human exposure — orforglipron was non-carcinogenic. A 26-week study in transgenic mice was also non-carcinogenic.

So why does it have a Boxed Warning?

Because the usual rodent on-target signal cannot answer the same question for this drug. The label says orforglipron is not pharmacologically active in rats or mice. It also says that other GLP-1 drugs active in rats produced C-cell changes and that orforglipron would be expected to have the same on-target class effect if it were active in rats.

The approved label does not pretend that a negative rat study settled the human question. Foundayo is active at the human GLP-1 receptor, and the label says the human relevance of the rodent class finding has not been determined. The box is a precaution about that unknown — not a finding that Foundayo caused rodent tumors.

Here is the part that bothers us. The sentence saying orforglipron did not produce tumors in rodents is in the full Boxed Warning your prescriber reads. It is not in the patient Medication Guide. The Medication Guide says only that medicines that work like Foundayo caused thyroid tumors in rodents and that nobody knows whether Foundayo will do so in people.

We read both documents in the same DailyMed record on the same day. If you are a Foundayo patient who got scared by the Medication Guide, you were scared by a document that left out the most reassuring line in the full warning.

Same medicine, different current label

Two comparisons prove why you have to check your exact product, not “GLP-1s” as a group:

Byetta vs. Bydureon BCise. Both contain exenatide. Byetta is immediate-release; Bydureon BCise is extended-release. The current Bydureon BCise label carries the thyroid Boxed Warning. The current Byetta label does not. Same active ingredient, different formulations, different current labels.

Soliqua vs. Xultophy. Both combine insulin with a GLP-1 medicine. Xultophy carries the Boxed Warning tied to its liraglutide component. Soliqua’s current label does not have the thyroid box. Same product category, opposite label result.

If a page tells you “all GLP-1s carry the same warning,” it has not opened the current labels.

You have the chart. Now make it about your exact product.

→ Check my exact medication — use the name on your box or prescription, then open the current primary label.

Check your exact medication

Use the exact product name. Do not stop at “semaglutide,” “tirzepatide,” or “a GLP-1.”

• Boxed Warning present: Ozempic injection, Ozempic tablets, Rybelsus, Wegovy, Mounjaro, Zepbound, Foundayo, Trulicity, Victoza, Saxenda, Xultophy, and Bydureon BCise.
• No Boxed Warning section in the current record: Byetta and Soliqua.
• Foundayo: yes, but its wording is different because its own rodent cancer studies produced no tumors.
• Generic or repackaged product: use the exact label dispensed with your product.
• Compounded product: it does not have FDA-approved prescribing information; use the compounded section below before drawing any conclusion from the lack of an FDA box.

Your next move is simple: open the source in the chart, confirm the product name and revision date, then read Section 4 and Section 5 — not only the black border.

What does the GLP-1 black box warning actually say?

“Boxed Warning” is the official FDA term. “Black box warning” is what people usually call it. On most warned GLP-1 labels, the box says the product caused thyroid C-cell tumors in rodents, that the human meaning is unknown, and that people with personal or family MTC or MEN 2 should not use it. Foundayo adds a fifth fact: its own rodent studies produced no tumors.

That is the common pattern:

1. Thyroid C-cell tumors appeared in rodent studies for most warned products.
2. The human relevance has not been determined.
3. MTC is the specific thyroid cancer named.
4. Personal or family MTC and MEN 2 are contraindications.
5. Foundayo says its own rodent studies were negative but keeps the class-based warning.

A Boxed Warning is FDA’s most prominent warning. It appears near the top of prescribing information, inside a border, so it is hard to miss.

What it does mean: this risk is important enough to display first and discuss before use.

What it does not mean: that the risk is proven in people, that every person has the same risk, that FDA regrets approving the drug, or that a product without this box is risk-free.

It is a visibility requirement, not a verdict.

For the full breakdown of how a Boxed Warning differs from a contraindication and a Section 5 warning, see GLP-1 contraindications vs. warnings vs. precautions. For a walkthrough of the whole label, see how to read a GLP-1 prescribing information label.

Is pancreatitis, gallbladder disease, or stomach paralysis in the boxed warning?

No. In every actual Boxed Warning section found in the 13 records we checked, the box is about thyroid C-cell tumors. Pancreatitis, severe stomach reactions, kidney injury from dehydration, gallbladder disease, and the anesthesia risk appear in Warnings and Precautions instead. Their exact section numbers vary by product.

This is one of the easiest label mix-ups to fix.

We pulled the map below from the Foundayo label, which we read from start to finish. Do not assume every other product uses the same numbers.

Other adverse reactions and postmarketing reports appear in Section 6 and vary by product.

Being outside the box does not make a risk unimportant. Pancreatitis is serious. So is pulmonary aspiration during anesthesia. They are simply documented somewhere else, and they belong in a different conversation with your prescriber than the thyroid warning does.

Where did the GLP-1 boxed warning come from, and does it prove risk in people?

The warning comes from lifetime rodent cancer studies. Most warned labels say the specific drug caused thyroid C-cell tumors in rats or mice and that the human relevance has not been determined. Foundayo is different: its own rodent studies produced no tumors, but its label keeps a class-based warning because the human meaning of the rodent class finding is still unknown.

Here is the piece almost nobody says cleanly: the labels draw a hard line between an animal finding and a human conclusion.

Here is what we cannot tell you

We can tell you exactly what the label says. We cannot tell you your personal risk.

Current evidence does not give anyone a precise personal percentage. The rodent findings are real. The human meaning remains unresolved in the approved labels. Anyone telling you the risk is zero is saying something the label does not say. Anyone telling you the box proves these medicines cause human thyroid cancer is also saying more than the label says.

If unresolved uncertainty is your personal dealbreaker, that is a legitimate position. Other treatment paths exist for weight management and type 2 diabetes. Ask your clinician about them instead of white-knuckling through something you are not at peace with. That reader should stop here and read our thyroid cancer risk evidence review before deciding what to ask next.

The labeled thyroid contraindication is narrow. Because of this warning, the “do not use” line names personal or family MTC and MEN 2. Outside those situations, the label does not give a general “do not use” order based only on the thyroid box. It tells prescribers to counsel patients about the warning and its symptoms. That is a much smaller instruction than the black border makes it feel.

The full human evidence — cohort studies, trials, reviews, and their limits — belongs on our GLP-1 and thyroid cancer risk page. We are not going to duplicate it here.

Who actually cannot use a GLP-1 because of this warning?

For products carrying this warning, the label names two situations: a personal or family history of medullary thyroid carcinoma (MTC), and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These are firm contraindications in Section 4, not soft cautions. The label says “family history”; it does not define how close the relative must be.

Two definitions, in plain words:

Medullary thyroid carcinoma (MTC) is a thyroid cancer that starts in the thyroid’s C-cells. The National Cancer Institute says MTC makes up about 3% to 4% of thyroid cancers. It is a different disease from the much more common thyroid cancers, and it is the cancer named in this warning.

MEN 2 is an inherited condition tied to changes in the RET gene and a very high chance of MTC. People may learn about it through a family diagnosis or genetic testing.

“Family history” — what counts?

The label says “personal or family history of MTC.” It does not say first-degree relative, immediate family, or close blood relative. So do not narrow it yourself and do not widen it into panic.

What to actually do:

1. Ask the relative — or whoever has the records — what type of thyroid cancer it was.
2. Look for the word medullary in the pathology report. That is the word that matters for this box.
3. Ask whether MEN 2 or a RET gene test was ever mentioned.
4. Bring what you find to your prescriber.

“Grandma had thyroid cancer” is not enough information to answer this question. It is also not a reason to assume the worst. NCI says MTC is only 3% to 4% of thyroid cancers, so most thyroid cancers are not MTC.

If this is you, stop here

If you have personal or family MTC, or MEN 2, do not use this page as clearance to start or continue anything. Contact your prescriber promptly and do not use an article to decide whether to take or skip your next dose. Other treatment paths exist, and this is exactly the conversation those options are for.

We are not going to send you to a telehealth signup. That would be indefensible, and we would rather lose you than do it.

I have a thyroid condition. Does the warning apply to me?

Not because of this specific MTC/MEN 2 contraindication unless your exact diagnosis is MTC or MEN 2. Hashimoto’s, hypothyroidism, Graves’ disease, goiter, thyroid nodules, and non-medullary thyroid cancers are not the diagnoses named in the box. That is not personal clearance; your exact history still belongs with your prescriber.

Here is the sort.

One easy wrong turn is someone with Hashimoto’s assuming they are automatically disqualified. Hashimoto’s itself is not listed as the MTC/MEN 2 contraindication. But you should hear what that means for you from a prescriber with your chart in front of them, not from a table on the internet.

Found yourself in that table? Turn it into a short question list.

→ Build my prescriber question list — use your exact product, thyroid history, family history, and symptoms to make a printable list.

Build your prescriber question list

Write down your answer to these four questions:

1. What exact product and formulation am I using or considering?
2. Have I ever had MTC, MEN 2, another thyroid cancer, a nodule, Hashimoto’s, or another thyroid diagnosis?
3. Has anyone in my family had MTC or MEN 2 — or do I only know the words “thyroid cancer”?
4. Do I have a new neck lump, lasting hoarseness, trouble swallowing, or trouble breathing?

Then bring the matching questions below:

Records to bring

• [ ] Your exact medication name and dose
• [ ] A photo of the box, bottle, pen, or vial
• [ ] Any thyroid pathology report
• [ ] The affected relative’s name and exact cancer type
• [ ] Any MEN 2 or RET test result
• [ ] A prior thyroid ultrasound report
• [ ] A calcitonin result, if one was already ordered
• [ ] Your current thyroid medicines
• [ ] Any planned surgery, procedure, anesthesia, or deep sedation

This question builder is not medical advice. It does not tell you whether you are safe, whether you qualify, or whether to take the next dose.

Should I get a calcitonin test or thyroid ultrasound before starting?

Several warned labels answer this directly: routine calcitonin testing and routine thyroid ultrasound are described as being “of uncertain value” for finding MTC early in patients using these drugs. The labels warn that testing everyone may lead to unnecessary procedures. Targeted testing for a symptom, nodule, abnormal result, or specific history is a different situation.

The label’s reasoning is straightforward. Calcitonin testing has low specificity, and thyroid disease is common. That means routine screening can create abnormal or borderline results that lead to more testing and procedures without clearly helping every patient.

The labels also give a reference point: people with MTC usually have calcitonin above 50 ng/L. If calcitonin was already measured and is elevated, the label says the patient should be evaluated. A thyroid nodule found on an exam or imaging should also be evaluated.

“Of uncertain value” does not mean “never test.” It means the label does not support routine screening of everyone only because they use a GLP-1 medicine.

Four questions worth asking

• “Is there anything in my history that gives us a specific reason to order calcitonin?”
• “Does my existing nodule need follow-up before I start?”
• “Would a result actually change what you prescribe?”
• “What result would lead you to send me to an endocrinologist?”

Symptoms to report — the four the labels name

You do not need to diagnose yourself. You need to know the four symptoms named in the labels and report them if they are new or do not go away.

None of these symptoms proves cancer. All of them are reasons to contact a health professional promptly instead of waiting for the next refill visit.

Do compounded semaglutide or tirzepatide products have an FDA boxed warning?

They do not have an FDA-approved Boxed Warning, because compounded products do not have FDA-approved prescribing information. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed. A missing FDA box is not proof that a compounded product is safer.

We need to be blunt here, because the wrong reading is genuinely dangerous.

The absence of a warning is not the presence of safety.

An FDA-approved label represents something specific: an approved package built from reviewed animal and human evidence, patient counseling language, a Medication Guide when required, and a public revision trail. A compounded product does not come with FDA-approved Prescribing Information, an FDA-approved Medication Guide, or the same public label history.

That does not make all compounding illegitimate. FDA says compounding can serve an important patient need when an FDA-approved medicine is not medically appropriate for a patient. It makes compounded medicine different, not equivalent.

In February 2026, FDA said promotional materials for non-FDA-approved compounded GLP-1 products cannot call them generic versions, say they are the same as FDA-approved drugs, say they use the same active ingredient, or say they are clinically proven to produce results. We follow that standard on every page of this site.

FDA has also warned about fraudulent compounded semaglutide and tirzepatide labels, including labels naming pharmacies that did not exist or did not make the product. The agency has received reports of dosing errors with compounded injectable semaglutide, including some cases that required hospitalization.

If you use a compounded product, ask these questions

• Which pharmacy actually made what is in my vial?
• Is that the same pharmacy named on the label?
• What exact concentration is printed on the vial?
• What does my prescribed dose equal in units on this syringe?
• What written safety information came with this exact vial?
• Who do I call about a side effect or dosing question?
• What screening did you do about my thyroid history before prescribing?

If the vial, the box, and the instructions do not agree with one another, stop and call the prescriber or compounder before you inject.

What changed in GLP-1 warnings in 2026?

On January 13, 2026, FDA requested removal of the suicidal behavior and ideation warning from Saxenda, Wegovy, and Zepbound after reviewing 91 placebo-controlled trials with 107,910 patients and finding no increased risk. Current labels record that removal in February 2026. The thyroid Boxed Warning stayed in place.

That distinction matters. “FDA removed a GLP-1 warning” does not mean “FDA removed the thyroid Boxed Warning.”

Here is the honest read on what that tells you. FDA did request removal of one warning after a large review found no increased risk, and the affected labels were changed. FDA has not removed the thyroid box. That does not prove human thyroid-cancer harm. It tells you the two warning questions are separate, and the current thyroid labels still describe the human relevance as unknown.

That is not a scare tactic. It is a fact with a date on it.

What should I do after reading a GLP-1 boxed warning?

Five steps. Name your exact product, check whether its current label has the box, identify your exact thyroid history, read Sections 4 and 5 instead of only the box, and bring focused questions to your prescriber. Do not start, stop, skip, or switch a prescription because of anything you read online — including this page.

1. Name the exact product

Not “semaglutide.” Not “a GLP-1.” Wegovy pen. Ozempic tablets. Zepbound. The answer follows the exact product and formulation, not only the ingredient name.

2. Check whether it has the box

Use the chart above. Open the source and note the revision date.

3. Get specific about your thyroid history

“Thyroid cancer” is not specific enough. Medullary, papillary, follicular, Hürthle cell, a nodule, and Hashimoto’s are not interchangeable answers.

4. Read past the box

Sections 4 and 5 contain contraindications and serious risks that may matter more to you personally than the thyroid warning does.

5. Ask one focused question

Not “Is this safe?” Try: “Given my family thyroid history, does the MTC contraindication apply to me?” That gives your prescriber a real question to answer.

Bring these to your appointment

• Your medication name and dose
• A photo of the box, bottle, pen, or vial
• Any thyroid pathology report you can get
• The relative’s name and exact cancer type
• Any MEN 2 or RET testing paperwork
• A prior ultrasound report, if you have one
• Your current thyroid medicines
• Any surgery or procedure coming up

What real patients say about this warning

We do not publish invented testimonials, and we will not use a customer quote to prove anything about cancer risk. But the emotional reaction to this warning is real and worth naming.

In a Wegovy discussion on Reddit, one person described a “nagging voice” that kept saying “cancer!” each time they took a dose. Another commenter asked the exact question this page answers: how close does a family member have to be for the warning to count?

Those comments are not medical evidence. They are evidence of the decision problem: the label is precise, but the fear it creates is not.

NCI says MTC is only 3% to 4% of thyroid cancers. The fear is reasonable. The scope of the warning is narrow. Getting from one to the other is the whole job of this page.

Where to go from here

If the MTC/MEN 2 contraindication does not match your history, you have cleared one label question — not the whole safety decision.

One honest note about what you just read. Every fact on this page — the Boxed Warning, the animal-study numbers, the Medication Guide wording, and the revision dates — exists because these approved products have a public regulatory paper trail. That is the thing you were able to check today. If that matters to you, it should factor into which treatment path you choose.

The right GLP-1 provider is not the same for everyone. It depends on your state, insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred form, and your budget. Because a general answer cannot resolve those for you, use The RX Index’s Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

If you selected personal or family MTC, or MEN 2, above, do not use a matching tool as medical clearance. Talk to your prescriber first.

→ Find My GLP-1 Path

How we built this page

Who made it: Written and edited by Kaden Coziar, Founder & Managing Editor of The RX Index. This page has not been reviewed by a clinician, and we do not claim otherwise.

How we made it: On August 5, 2026, we opened 13 U.S. brand-name DailyMed label records covering 14 product and formulation entries. We checked every record for a Boxed Warning heading, Section 4, the thyroid-safety language, and the current prescribing-information revision marker. We reviewed Section 13.1 for Ozempic injection, Victoza, Soliqua, and Foundayo. We read the Foundayo Prescribing Information and Medication Guide side by side. We checked DailyMed marketing-end metadata where it was relevant, but we did not treat that metadata as proof of live pharmacy stock. We did not infer any warning from drug class alone.

Why it exists: Because nobody should have to open 13 dense drug-label records to answer one question — “Does my exact medicine have the warning, and what does it mean for me?”

What this page is not: medical advice, a diagnosis, a risk calculation, or clearance to start, stop, skip, or switch anything.

Corrections: Found an error? Use the contact link in the site footer and send the primary source. We date and log every correction that changes a fact on this page.

Version 1.0 — verified August 5, 2026.

Frequently asked questions about GLP-1 boxed warnings

Is “black box warning” the same as “Boxed Warning”?

Yes. “Boxed Warning” is FDA’s official term. “Black box warning” is the common name for it.

Does Ozempic have a boxed warning?

Yes. The current Ozempic injection label and the shared oral-semaglutide label covering Ozempic tablets both carry the thyroid C-cell tumor Boxed Warning and list personal or family MTC and MEN 2 as contraindications.

Does Wegovy have a boxed warning?

Yes. The current Wegovy label covers injection, Wegovy HD, and tablets. The label carries the thyroid C-cell tumor Boxed Warning.

Do Mounjaro and Zepbound have boxed warnings?

Yes. Both tirzepatide labels carry the thyroid C-cell tumor Boxed Warning and the MTC/MEN 2 contraindication.

Does Foundayo have a boxed warning?

Yes, but its wording is different. The label says orforglipron is not pharmacologically active in rats or mice and produced no tumors in its rodent studies. The box remains because the human relevance of the GLP-1 receptor-dependent rodent class finding is still unknown.

Which GLP-1 products do not have the thyroid Boxed Warning?

In our August 2026 review, the current Byetta and Soliqua brand-name records do not contain a Boxed Warning section. Both still carry serious warnings elsewhere in their labels.

Is Bydureon BCise still marketed?

DailyMed lists a marketing end date of October 31, 2025 for the Bydureon BCise record. A label can remain online after its marketing end date, so the record should not be read as proof of current pharmacy stock.

Is pancreatitis part of the GLP-1 boxed warning?

No. Pancreatitis appears in Warnings and Precautions for products where it is listed. It is a serious risk — just not part of the thyroid Boxed Warning.

Does Hashimoto’s disqualify me?

Hashimoto’s is not the condition named in the MTC/MEN 2 contraindication. That is not personal medical clearance. Tell your prescriber and go through your full thyroid history.

How close does a relative have to be for “family history” to count?

The labels do not define a degree of relation. Confirm whether the relative actually had medullary thyroid carcinoma, then ask your prescriber how the label applies to your family history.

My relative had thyroid cancer, but nobody knows what kind. What now?

Get the pathology report and look for the word “medullary.” Do not guess from the fact that the person had thyroid surgery. Most thyroid cancers are not MTC.

Does having my thyroid removed make the warning irrelevant?

Not by itself. The reason for the surgery matters. A past diagnosis of MTC is still a personal history of MTC after the thyroid is removed.

Should I stop my medication after reading the warning?

Do not make a dose decision because of a web page. Contact your prescriber, give them your exact product and thyroid history, and ask what to do about the next scheduled dose.

Does everyone need a calcitonin test before starting?

Several labels describe routine calcitonin testing and thyroid ultrasound as being of uncertain value for this purpose and warn that routine testing may lead to unnecessary procedures. Targeted testing for a documented reason is different.

Do compounded GLP-1 products have an FDA boxed warning?

They do not have an FDA-approved Boxed Warning because they do not have FDA-approved prescribing information. That does not mean they are safer. It means FDA has not approved a product-specific label for them.

Can FDA remove this warning later?

Yes, drug labels can change. In January 2026, FDA requested removal of suicidal behavior and ideation language from Saxenda, Wegovy, and Zepbound after a 91-trial review found no increased risk. Current labels record that removal, while the thyroid Boxed Warning remains.

What if I am taking a generic or repackaged product?

Use the exact label that came with your prescription. This ledger tracks the brand-name records and does not claim to represent every NDC or repackager.

Sources

All DailyMed records below were accessed and checked on August 5, 2026.

1. OZEMPIC injection (semaglutide) Prescribing Information, revised 5/2026 — Boxed Warning, Sections 4, 5.1, and 13.1
2. RYBELSUS and OZEMPIC tablets (semaglutide) Prescribing Information, revised 1/2026 — shared label record
3. WEGOVY injection, WEGOVY HD, and WEGOVY tablets Prescribing Information, revised 6/2026
4. MOUNJARO (tirzepatide) Prescribing Information, revised 4/2026
5. ZEPBOUND (tirzepatide) Prescribing Information, revised 4/2026
6. FOUNDAYO (orforglipron) Prescribing Information and Medication Guide, revised 4/2026 — Boxed Warning, Sections 4, 5.1–5.9, and 13.1
7. TRULICITY (dulaglutide) Prescribing Information, revised 3/2026
8. VICTOZA (liraglutide) Prescribing Information, revised 10/2025 — Boxed Warning and Section 13.1
9. SAXENDA (liraglutide) Prescribing Information, revised 6/2026
10. XULTOPHY 100/3.6 Prescribing Information, revised 10/2025
11. BYDUREON BCise (exenatide extended-release) Prescribing Information, revised 5/2025
12. BYETTA (exenatide) Prescribing Information, revised 9/2025
13. SOLIQUA 100/33 Prescribing Information, revised 3/2026 — Sections 4 and 13.1
14. FDA approval announcement for Foundayo, April 1, 2026
15. FDA Drug Safety Communication, January 13, 2026 — removal request for suicidal behavior and ideation language
16. FDA: Compounding and the FDA — Questions and Answers
17. FDA statement on non-FDA-approved GLP-1 promotional claims, February 6, 2026
18. FDA’s concerns with unapproved GLP-1 drugs used for weight loss
19. FDA description of a Boxed Warning as its most prominent warning
20. National Cancer Institute: Medullary Thyroid Cancer
21. Reader-language source: “Anyone else freaked out by the potential thyroid cancer warning?” — used only to describe reader fear and questions, not as medical evidence

Related reads

• GLP-1 contraindications vs. warnings vs. precautions — what each FDA label category means
• How to read a GLP-1 prescribing information label — where to find every section yourself
• GLP-1 medications and thyroid cancer risk — the full human-evidence review
• Is GLP-1 safe? 16 checks before you start — the broader safety picture

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz. → Find My GLP-1 Path

This page explains current U.S. drug labeling. It is not medical advice, a diagnosis, a risk calculation, or a prescribing decision. Labels and individual circumstances change. Do not begin, stop, skip, or switch a prescription without speaking to the clinician responsible for your care.